270 related articles for article (PubMed ID: 19758663)
1. Editorial comment.
Kamat AM
J Urol; 2009 Nov; 182(5):2203. PubMed ID: 19758663
[No Abstract] [Full Text] [Related]
2. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment.
Witjes JA
Urology; 2009 Dec; 74(6):1281. PubMed ID: 19962528
[No Abstract] [Full Text] [Related]
4. Editorial comment.
Herr HW
Urology; 2009 Dec; 74(6):1280-1; author reply 1281. PubMed ID: 19962527
[No Abstract] [Full Text] [Related]
5. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
McHugh LA; Griffiths TR
BJU Int; 2004 Jul; 94(1):193. PubMed ID: 15217467
[No Abstract] [Full Text] [Related]
6. BCG and bladder cancer.
Gilling PJ
N Z Med J; 2010 Nov; 123(1325):8-9. PubMed ID: 21317955
[No Abstract] [Full Text] [Related]
7. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
Witjes JA
Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
[No Abstract] [Full Text] [Related]
8. [International Consensus Panel--treatment strategies for superficial bladder cancer].
Adler S; St Niclas M
Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
[No Abstract] [Full Text] [Related]
9. Management of BCG "Failures".
Palou Redorta J
Eur Urol; 2006 May; 49(5):779-80. PubMed ID: 16616207
[No Abstract] [Full Text] [Related]
10. Editorial comment.
Stenzl A
J Urol; 2009 Oct; 182(4):1317; discussion 1317. PubMed ID: 19683279
[No Abstract] [Full Text] [Related]
11. The search of new biomarkers in the prediction of BCG response in patients with high-risk NMIBC.
Martinez Rodriguez RH; Amon Sesmero JH
World J Urol; 2021 Feb; 39(2):629-630. PubMed ID: 32248362
[No Abstract] [Full Text] [Related]
12. Treatment of high-risk, non-muscle-invasive bladder cancer.
Lerner SP
Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
[No Abstract] [Full Text] [Related]
13. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Palou J; Rodríguez O; Segarra J; Rosales A
J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451
[No Abstract] [Full Text] [Related]
14. T1G3 bladder tumours: the case for conservative treatment.
Turner W
Eur Urol; 2004 Apr; 45(4):401-5. PubMed ID: 15041101
[No Abstract] [Full Text] [Related]
15. Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
Sylvester RJ
Eur Urol; 2008 May; 53(5):1002. PubMed ID: 17950990
[No Abstract] [Full Text] [Related]
16. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes.
Brandau S
J Urol; 2009 Apr; 181(4):1532-3. PubMed ID: 19230928
[No Abstract] [Full Text] [Related]
17. Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
Inman BA
J Urol; 2006 May; 175(5):1960; author reply 1960-1. PubMed ID: 16600806
[No Abstract] [Full Text] [Related]
18. Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer.
Campi R; Seisen T; Roupret M
Eur Urol Focus; 2018 Jul; 4(4):472-480. PubMed ID: 30172757
[No Abstract] [Full Text] [Related]
19. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
20. Discontinuance of bacille Calmette-Guérin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence.
Takeda T; Kikuchi E; Yuge K; Matsumoto K; Miyajima A; Nakagawa K; Oya M
Urology; 2009 Jun; 73(6):1318-22. PubMed ID: 19232694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
